HK Stock Market Move | BIODLINK-B(01875) rose nearly 12% in the closing session. The company is a leading enterprise in the CDMO transformation, and prices of future orders are expected to increase.

BIODLINK-B (01875) rose nearly 12% at the close, up 11.62% as of the time of writing, at HK$5.86, with a transaction volume of HK$24,741.4 million. On the news front, WUXI XDC's cash tender offer for Dongyao Pharmaceutical has been accepted for 60% of Dongyao Pharmaceutical's equity, and the share offer has officially taken effect. Guotou Securities International pointed out that Dongyao Pharmaceutical has achieved a magnificent transformation, evolving from a traditional pharmaceutical company to a leading player in the CDMO sector. Leveraging deep synergy with Pharmaron, the company's CDMO business is expected to continue to grow steadily in the future, further consolidating its industry position. It is expected that CDMO order prices will continue to increase in the future.